BioCentury
ARTICLE | Clinical News

Merck's Keytruda improves OS in NSCLC study

October 27, 2015 12:02 AM UTC

Merck & Co. Inc. (NYSE:MRK) said top-line data showed Keytruda pembrolizumab significantly increased overall survival compared with docetaxel in the Phase II/III KEYNOTE-010 trial to treat metastatic non-small cell lung cancer in previously treated patients with tumors expressing PD-L1.

FDA granted accelerated approval to Keytruda in the indication earlier this month, and the drug's label says its survival benefit has not been established. Merck said it would submit the new data to FDA by YE15 and in the EU in early 2016. ...